|
End-of-day quote
Other stock markets
|
||
| - USD | - |
|
| 07-03 | PFIZER INC : Buy rating from Jefferies | ZD |
| 07-02 | US Committee Launches Probe Against Five Drugmakers Over China Clinical Trials | MT |
| Market Cap | 139B 121B 111B 104B 197B 13,198B 200B 1,337B 520B 6,487B 520B 509B 22,355B | P/E 2026 * |
11.4x | P/E 2027 * | 12.3x |
|---|---|---|---|---|---|
| Enterprise Value | 187B 163B 150B 140B 265B 17,794B 269B 1,802B 701B 8,747B 701B 686B 30,141B | EV / Sales 2026 * |
3.03x | EV / Sales 2027 * | 3.05x |
| Free-Float |
59.06% | Yield 2026 * |
7.2% | Yield 2027 * | 7.17% |
Last Transcript: Pfizer Inc
| Manager | Title | Age | Since |
|---|---|---|---|
Albert Bourla
CEO | Chief Executive Officer | 64 | 31/12/2018 |
David Denton
DFI | Director of Finance/CFO | 60 | 01/05/2022 |
| Chief Tech/Sci/R&D Officer | - | 31/12/2006 |
| Director | Title | Age | Since |
|---|---|---|---|
Suzanne Johnson
BRD | Director/Board Member | 68 | 31/08/2007 |
Shantanu Narayen
BRD | Director/Board Member | 62 | 26/09/2013 |
Albert Bourla
CHM | Chairman | 64 | 31/12/2019 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.86% | +0.48% | +55.50% | +163.08% | 1,082B | |
| +3.57% | +3.29% | +68.60% | +61.03% | 633B | |
| +3.99% | +3.05% | +37.93% | +93.37% | 461B | |
| +3.86% | +1.64% | +32.57% | +24.89% | 338B | |
| -0.56% | +0.96% | +41.67% | +39.35% | 299B | |
| -0.08% | +1.30% | +32.15% | +44.48% | 291B | |
| -1.54% | +2.81% | -25.35% | -39.61% | 222B | |
| +3.55% | +4.41% | +25.45% | +66.28% | 202B | |
| +4.21% | +2.65% | +17.47% | +71.11% | 163B | |
| Average | +2.10% | +4.58% | +31.78% | +58.22% | 410.27B | |
| Weighted average by Cap. | +2.25% | +5.53% | +42.31% | +83.31% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 61.69B 53.93B 49.56B 46.2B 87.62B 5,874B 88.95B 595B 231B 2,887B 232B 227B 9,949B | 59.32B 51.86B 47.66B 44.42B 84.26B 5,648B 85.54B 572B 222B 2,776B 223B 218B 9,568B |
| Net income | 11.07B 9.68B 8.89B 8.29B 15.72B 1,054B 15.96B 107B 41.51B 518B 41.55B 40.66B 1,785B | 10.72B 9.37B 8.61B 8.03B 15.22B 1,020B 15.45B 103B 40.18B 502B 40.23B 39.36B 1,728B |
| Net Debt | 48.28B 42.2B 38.78B 36.15B 68.57B 4,597B 69.61B 466B 181B 2,259B 181B 177B 7,786B | 42.08B 36.78B 33.8B 31.51B 59.76B 4,006B 60.67B 406B 158B 1,969B 158B 155B 6,786B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Select your edition
All financial news and data tailored to specific country editions
